According to the World Health Organization, brain tumors account for around 2% of all adult cancers and 1.9% of all childhood cancers. Gliomas represent about 20% of all brain and CNS tumors. In line with the #Servier2030 ambition, our aim is to become an innovative player focused on hard-to-treat cancers. We develop treatments 🔬 for cancer patients, with a particular focus on digestive cancers, glioma or brain tumors, hematological cancers, and pediatric cancers. Recently, we had the pleasure of speaking 🗣️ with Maya Duvillard, a patient with oligodendroglioma, who tells us about her disease journey. 🎥 Watch her inspiring story on our Instagram account and get her perspectives on the fight against cancer 👉 https://lnkd.in/e4mSA-As You can also find Maya @cmayaduvillard on Instagram. #Glioma #BrainTumor #MovedByYou
Servier
Fabrication de produits pharmaceutiques
Committed to therapeutic progress to serve patient needs
À propos
Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com
- Site web
-
https://servier.com
Lien externe pour Servier
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- + de 10 000 employés
- Siège social
- Suresnes
- Type
- Société civile/Société commerciale/Autres types de sociétés
Lieux
-
Principal
50 rue Carnot
92150 Suresnes, FR
Employés chez Servier
Nouvelles
-
📣 In the first issue of Insights by Servier, we highlight the start-up Palm Therapeutics, which has joined the FAST Fall cohort of the California Life Sciences (CLS) program, an initiative that supports innovative biotech start-ups in California. 💪 The FAST program provides extensive coaching, helping start-ups refine their business strategies and prepare for successful fundraising. 🙌 At Servier, we sponsor start-ups for the FAST program, further enhancing the collaborative efforts in life sciences and biotechnology. Read the entire article 👉 https://lnkd.in/gmvpqRcg #WeAreServier #InsightsByServier #incubator
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
-
🤩 We were pleased to welcome around forty five talented young scientists of our #SHINEDocs community for the annual event "SEEDPODS Day" held at our R&D Institute in Paris-Saclay. During this event, they presented their research projects in 3 minutes in an easy-to-understand way. The objective? Accelerate research and innovation to benefit patients. Congratulations to the winners of flashtalks and poster presentations! 🥇 1st best flashtalk Raphael R. Steimbach 🥈 2nd best flashtalk Julie Le Naour 🥉 3rd best flashtalk Clara Ramón Lozano 👥 Audience award Daniel Herrero Saboya ✨ Long version flashtalk award Emilie Gentilini 🥇 1st best poster Marius Halliez Thank you to our 31 partners for supporting this event. Learn more about the SEEDPODS Day 👉 https://lnkd.in/ehahbiHP #innovation #talent #scientists #ParisSaclay #research #patient
-
Servier a republié ceci
What are the solutions for better patient adherence to treatment, as part of the wider steps that can be taken to improve #ESCGuidelines implementation? Tamara Krcmar of Servier brings the industry perspective to the table 👇 #ESCardioCRT
-
▶️ "How can science and medical innovations support #cancer patients?": Watch our #THRPTX first panel discussion complete replay! Our experts discussed 5 key topics to shape future therapies: 🔹Patient-centered care: Personalizing treatments, with Hans Scheurer 🔹Patient involvement: Making them co-researchers in clinical trials, with Dr Ines Vaz-Luis 🔹R&D challenges: Addressing numerous obstacles, with Dr Susan Pandya, M.D. 🔹Precision medicine: Maintaining therapy effectiveness, with Prof Hsin-An Hou 🔹Mutation prevention: Early detection strategies, with Prof Andrew Wei 👉 🔎 The first Therapeutic Innovation Summit (THRPTX) took place on 18 June 2024 at our R&D Institute in Paris-Saclay, focusing on bringing together over 200 global experts to shape the horizons of an innovative therapeutic future in #oncology. #WeAreServier #MovedByYou
-
🔬 For the latest issue of Insights by Servier, we had the opportunity to analyze the impact of incubators on the development and business-growth of start-ups. 💪 Since 2022, we have been sponsoring start-ups for the FAST program, an incubator offered by California Life Sciences (CLS) that provides innovative biotech entrepreneurs with customized support. Selected candidates receive 12 intensive weeks of fundraising coaching and guidance in project administration, as well as the opportunity for daily contact with other players in the sector. Follow this link to read the entire article on start-ups, incubators, and their stakeholders 👉 https://lnkd.in/gmvpqRcg #WeAreServier #InsightsByServier #incubator Palm Therapeutics
-
How can works of art be the means for conveying the voice of patients at our R&D Institute in Paris-Saclay? Inspired by an original idea 💡 from the Servier Saclay Research & Development Patient Board, Art in Saclay exemplifies our desire to create strong ties between patients, R&D, and art. 👨🎨 The exhibition opened in June 2024. It bears witness to representations of patients’ voices, experiences and lives, at the very heart of our R&D Institute in Paris-Saclay and within range of researchers. These unprecedented encounters between artists and patients are on display for all to see through the original works that testify to their meeting, as are the works by talented patient-artists, direct expressions of the patient voice. Listen 🎥👇 to Marta Garcia Manrique, Chief Patient Officer R&D, share with us the genesis of this project and its challenges. Learn more about the Art in Saclay project 👉 https://swll.to/JUdK2 #patient #art #WeAreServier #MovedByYou
-
💬 For the first issue of Insights by Servier, we had the opportunity to interview Mathieu Lamiaux, Managing Director and Senior Partner at Boston Consulting Group (BCG), and Jerome Klein, Head of Corporate Strategy at Servier, about the opportunities and challenges of being a mid-size company in the pharmaceutical sector. 📣 Listen to Mathieu Lamiaux talk about the role of mid-size pharmaceutical companies and how that can bring its own rewards. Read the full interview with Mathieu Lamiaux and Jerome Klein on the opportunities and challenges for mid-size pharma in the latest issue of Insights by Servier 👉 https://lnkd.in/eNQwqyFC #WeAreServier #InsightsByServier #MidSizePharma
-
-
🎉 Congratulations to kyron.bio, winner of our Golden Ticket to Spartners by Servier & BioLabs France! kyron.bio is at the forefront of synthetic biology, developing advanced biomanufacturing processes for sustainable production. Their expertise lies in engineering microorganisms to produce high-value compounds, addressing global challenges in health, agriculture, and the environment with eco-friendly and cost-effective solutions. As a part of this year’s contest, kyron.bio will benefit from the latest research equipment, shared infrastructure, and numerous programs and services offered in Spartners by Servier & BioLabs. Learn more about Spartners by Servier & BioLabs France 👉 https://lnkd.in/eBa9FKzG #innovation #startup #biotech
-
Pharmaceutical companies can be divided into 3 major groups: ➡️ Biotech companies ➡️ Mid-size pharma companies ➡️ Big-pharma companies Read the full interview with Mathieu Lamiaux and Jerome Klein as they talk about the opportunities and challenges for mid-size pharma in the latest issue of Insights by Servier 👉 https://lnkd.in/eNQwqyFC #WeAreServier #InsightsByServier #PharmaceuticalIndustry
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn